Fortis Healthcare Limited has delivered impressive financial performance for the quarter ended December 31, 2025, demonstrating strong growth across its healthcare verticals. The leading integrated healthcare delivery service provider reported consolidated revenues of INR 2,265 Cr, marking a significant 17.5% increase compared to Q3 FY25.

Financial Performance Highlights

The company's consolidated financial results showcase robust operational efficiency and revenue expansion across both hospital and diagnostics businesses.

For the nine-month period ended December 31, 2025, consolidated revenues reached INR 6,763 Cr, up 17.1% from INR 5,776 Cr in the corresponding previous period. Operating EBITDA for 9M FY26 stood at INR 1,553 Cr, representing a 34.7% increase with margins expanding to 23.0% from 20.0%.

Hospital Business Drives Growth

The hospital business segment emerged as a key growth driver, reporting revenues of INR 1,938 Cr in Q3 FY26, up 19.4% from INR 1,623 Cr in Q3 FY25. Operating EBITDA for the hospital business increased by 28.9% to INR 420 Cr, with margins improving to 21.7% from 20.0% in the previous year.

Revenue growth was primarily driven by a 14% increase in occupied beds compared to Q3 FY25, with occupied beds reaching 3,189 versus 2,790 in the previous year. Focus specialties including Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopedics, and Renal Sciences contributed 61% to overall hospital business revenues, growing 19% year-over-year.

Diagnostics Business Shows Recovery

The diagnostics business reported gross revenues of INR 371 Cr in Q3 FY26, up 8.3% from INR 342 Cr in Q3 FY25. Operating EBITDA margin improved significantly to 23.1% from 14.4% in the corresponding previous quarter.

Agilus Diagnostics conducted approximately 9.94 million tests during Q3 FY26 compared to 9.59 million tests in Q3 FY25. The network expansion strategy continued with total customer touchpoints reaching 4,370 as of December 31, 2025.

Strategic Acquisitions and Expansion

Fortis Healthcare strengthened its market presence through strategic acquisitions and facility launches. In January 2026, the company acquired the 125-bedded People Tree Hospital in Yeshwanthpur, Bengaluru, for INR 430 Cr through a 100% acquisition of TMI Healthcare Pvt. Ltd. This acquisition includes the underlying land and building along with an adjacent land parcel, enabling future expansion to over 300 beds.

In November 2025, the company launched 'Adayu', a 36-bedded specialized mental health care facility in Gurugram, offering evidence-based treatments through a multidisciplinary approach.

Financial Position and Outlook

The company's net debt as of December 31, 2025, stood at INR 2,547 Cr with a Net Debt to EBITDA ratio of 1.24x compared to 0.41x as of December 31, 2024. The increase in debt was primarily due to funds raised to part-finance the acquisition of the PE stake in Agilus Diagnostics and the acquisition of Shrimann Hospital in Jalandhar, Punjab.

Dr. Ashutosh Raghuvanshi, MD and CEO of Fortis Healthcare, highlighted the healthy growth across key specialties, particularly noting that Renal Sciences and Orthopedics grew 27% and 20% respectively over the corresponding previous period. The company continues to progress on brownfield expansion plans while evaluating further inorganic opportunities in existing clusters.

Fortis Healthcare Limited has formally notified stock exchanges about comprehensive arrangements for its quarterly financial performance review. The healthcare major will present its third-quarter results to investors and stakeholders through multiple engagement channels following regulatory compliance procedures.

Board Meeting Details

The company has scheduled a Board of Directors meeting for Friday, February 13, 2026, with a specific agenda to consider and approve crucial financial documents. The meeting will focus on reviewing comprehensive financial performance across different business segments.

Conference Call Schedule

Following the board meeting, Fortis Healthcare Limited has arranged a conference call to discuss the financial results with investors and analysts. The virtual meeting will provide detailed insights into the company's quarterly and nine-month performance.

Dial-in Information

The company has provided comprehensive dial-in details for both domestic and international participants to ensure broad accessibility for the conference call.

Trading Window Restrictions

In accordance with regulatory compliance requirements, Fortis Healthcare Limited has implemented mandatory trading restrictions for company securities. The trading window closure ensures fair market practices during the financial results announcement period.

Regulatory Compliance

The board meeting and conference call notifications have been issued in strict compliance with Securities and Exchange Board of India regulations. The company has fulfilled its disclosure obligations under multiple regulatory frameworks to ensure transparency in corporate governance. The notifications were filed under Regulation 29, 30, and 50 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.